The PREFECT study started in 2013. Electronvulsive therapy (ECT) is a very effective treatment for depression. However, the effect varies among individuals and some suffer from side-effects. More knowledge is needed to better determine who and for what indication the treatment benefits the most.
The aim of the study is to identify factors that predict who will benefit the most from ECT and who should be offered alternative treatments. The markers studied will include genetic variation as well as blood borne endogenous molecules. The final aim of the study is to provide tools that can be used to tailor treatment to suit individual patient needs.
The study has been approved by the regional ethics comitttee in Stockholm (Dnr 2012/169-31/1) and is financed by the Foundation for Strategic research in Sweden. The study is coordinated from the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in partnership with the quality register for ECT.
For more information about the PREFECT study